Prediction of immunotherapy efficacy for pulmonary lymphoepithelioma-like carcinoma using baseline routine blood tests and serum tumor markers: a multicenter retrospective study
Xiongwen Yang, Yuanwei Liang, Hao Hu, Yubin Zhou, Huiyin Deng, Jian Huang, Maoli Liang, Zihao Yuan, Longyan Dong, Yi Xiao · 2025
Read Prediction of immunotherapy efficacy for pulmonary lymphoepithelioma-like carcinoma using baseline routine blood tests and serum tumor markers: a multicenter retrospective study by Xiongwen Yang, Yuanwei Liang, Hao Hu, Yubin Zhou, Huiyin Deng, Jian Huang, Maoli Liang, Zihao Yuan, Longyan Dong, Yi Xiao (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12709023.txt.
Description
Xiongwen Yang and nine colleagues build a blood-test score to predict who benefits from immunotherapy for a rare lung cancer. Pulmonary lymphoepithelioma-like carcinoma is linked to Epstein-Barr virus, and the standard PD-L1 test predicts checkpoint inhibitor response poorly. The team analyzed 254 patients treated across six Chinese centers.
Their composite score combines routine blood indices and serum tumor markers, fitted against progression-free survival. High scores meant much shorter survival in both training and validation groups, and the score outperformed PD-L1, which lost significance in adjusted models. Nomograms using the score discriminated well. The authors pitch the cheap, universally available test as a practical aid for individualized treatment decisions.
Catalog record
| CREATOR | Xiongwen Yang, Yuanwei Liang, Hao Hu, Yubin Zhou, Huiyin Deng, Jian Huang, Maoli Liang, Zihao Yuan, Longyan Dong, Yi Xiao |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |